- Home
- GNPX vs MTNB Comparison
GNPX vs MTNB Comparison
Compare GNPX & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNPX | MTNB |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.6M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GNPX | MTNB |
|---|---|---|
| Price | $2.63 | $2.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 160.2K | ★ 518.7K |
| Earning Date | 11-13-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $119,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.17 | $0.15 |
| 52 Week High | $12.97 | $3.05 |
Technical Indicators
Market Signals| Indicator | GNPX | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 33.70 | 85.37 |
| Support Level | $1.88 | $0.56 |
| Resistance Level | $3.11 | N/A |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | -0.04 | 0.30 |
| Stochastic Oscillator | 11.33 | 82.41 |
Price Performance
Historical ComparisonAbout GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.